This paper provides experienced insights for biopharmaceutical professionals who are interested in optimizing their ...

Renaissance will optimize the formulation of intranasal Foralumab and assist with scaling up production for clinical trials.

Chief Science Officer, Peter Surman, shares insight on why pharmaceutical companies should consider softgels for their next ...

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

The U.S. Food and Drug Administration (FDA) has approved Fapon Biopharma’s Investigational New Drug (IND) application for ...

Magnet Biomedicine, a biopharmaceutical company advancing molecular glue discovery, has entered a collaboration and license ...